EP
LAB icon

Essential Partners’s Standard BioTools LAB Stock Holding History

Essential Partners’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$863 Sell
1,049
-1,623
-61% -$1.53K ﹤0.01% 2301
2026
Q1 		$2.46K Buy
2,672
+1,108
+71% +$1.34K ﹤0.01% 1914
2025
Q4 		$2K Sell
1,564
-314
-17% -$422 ﹤0.01% 1798
2025
Q3 		$2.44K Hold
1,878
– – ﹤0.01% 1726
2025
Q2 		$2.25K Buy
+1,878
New +$2.08K ﹤0.01% 1281

Other funds holding LAB

CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Essential Partners's LAB Position: Q2 2026 in Review

Essential Partners reduced its Standard BioTools (LAB) stake by 61% in Q2 2026, selling an estimated $1.53K and leaving 1,049 shares worth $863. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

Essential Partners first reported a position in LAB in Q2 2025 and has held it in 5 quarters since. The position peaked at $2.46K in Q1 2026. 144 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Essential Partners held 1,049 shares of Standard BioTools worth $863 as of Q2 2026.
  • Essential Partners sold 1,623 Standard BioTools shares in Q2 2026, an estimated $1.53K.
  • Standard BioTools made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2301 holding.
  • Essential Partners first reported a position in Standard BioTools in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Standard BioTools position peaked at $2.46K in Q1 2026.
  • 144 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.